Nuvalent (NUVL)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Nuvalent (NUVL)
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Key Insights
Critical company metrics and information
Share Price
$94.31Market Cap
$6.70 BillionTotal Outstanding Shares
65.62 Million SharesTotal Employees
127Dividend
No dividendIPO Date
July 29, 2021SIC Description
Pharmaceutical PreparationsHomepage
https://www.nuvalent.com
Historical Stock Splits
If you bought 1 share of NUVL before March 10, 2017, you'd have 0.00 shares today.
Execution Date | Split Amount |
---|---|
March 10, 2017 | 1-for-1200000 (Reverse Split) |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities, Continuing | $-45.82 Million |
Net Cash Flow From Financing Activities | $550.27 Million |
Net Cash Flow From Financing Activities, Continuing | $550.27 Million |
Net Cash Flow From Investing Activities | $-212.91 Million |
Net Cash Flow From Operating Activities | $-45.82 Million |
Net Cash Flow | $291.54 Million |
Net Cash Flow, Continuing | $291.54 Million |
Net Cash Flow From Investing Activities, Continuing | $-212.91 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Nonoperating Income/Loss | $-7.97 Million |
Diluted Average Shares | $65.68 Million |
Basic Average Shares | $65.68 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Revenues | $8.70 Million |
Net Income/Loss Attributable To Parent | $-84.34 Million |
Operating Income/Loss | $-76.33 Million |
Research and Development | $60.55 Million |
Provision For Loan, Lease, And Other Losses | $0.00 |
Income/Loss From Continuing Operations Before Tax | $-84.31 Million |
Income/Loss From Continuing Operations After Tax | $-84.34 Million |
Interest Income/Expense Operating, Net | $8.70 Million |
Interest Income/Expense After Provision For Losses | $8.70 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-84.34 Million |
Diluted Earnings Per Share | $1.28 |
Other Operating Expenses | $15.78 Million |
Benefits Costs and Expenses | $93.00 Million |
Net Income/Loss | $-84.34 Million |
Costs And Expenses | $93.00 Million |
Basic Earnings Per Share | $1.28 |
Income Tax Expense/Benefit | $40000.00 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Operating Expenses | $76.33 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Current Liabilities | $51.13 Million |
Equity | $1.12 Billion |
Noncurrent Liabilities | $16.60 Million |
Noncurrent Assets | $9.18 Million |
Liabilities And Equity | $1.19 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Assets | $1.19 Billion |
Liabilities | $67.73 Million |
Equity Attributable To Parent | $1.12 Billion |
Accounts Payable | $15.93 Million |
Current Assets | $1.18 Billion |
Other Current Liabilities | $28.37 Million |
Wages | $6.83 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.